GoodRx Holdings, Inc. (GDRX) Misses Q3 EPS by 1c ; Offers Guidance

GoodRx Holdings, Inc. (NASDAQ: GDRX) reported Q3 EPS of $0.08, $0.01 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $195.3 million versus the consensus estimate of $195.66 million.

GUIDANCE:

GoodRx Holdings, Inc. sees Q4 2024 revenue of ~$200 million, versus the consensus of $206.2 million.

GoodRx Holdings, Inc. sees FY2024 revenue of ~$794 million, versus the consensus of $800.7 million.

For earnings history and earnings-related data on GoodRx Holdings, Inc. (GDRX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• FDA launches Operation TrialBlazer to accelerate drug research
• OpenAI launches cybersecurity tools and open-source patching program